359 related items for PubMed ID: 22869678
1. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
Chen S, Dong Y, Yin Y, Krucoff MW.
Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
[Abstract] [Full Text] [Related]
2. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC, Aronoff SC.
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[Abstract] [Full Text] [Related]
3. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S, Dong Y, Kiuchi MG, Wang J, Li R, Ling Z, Zhou T, Wang Z, Martinek M, Pürerfellner H, Liu S, Krucoff MW.
JAMA Pediatr; 2016 Dec 01; 170(12):1156-1163. PubMed ID: 27749951
[Abstract] [Full Text] [Related]
4. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
Hu JW, Zhou ZS, Yang L, Zheng CN, Wang KD.
Zhonghua Yi Xue Za Zhi; 2011 May 17; 91(18):1259-64. PubMed ID: 21756798
[Abstract] [Full Text] [Related]
5. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators.
Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251
[Abstract] [Full Text] [Related]
6. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
Lancet Child Adolesc Health; 2018 Dec 28; 2(12):855-862. PubMed ID: 30337183
[Abstract] [Full Text] [Related]
7. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.
Yang TJ, Lin MT, Lu CY, Chen JM, Lee PI, Huang LM, Wu MH, Chang LY.
J Microbiol Immunol Infect; 2018 Jun 28; 51(3):321-331. PubMed ID: 28927685
[Abstract] [Full Text] [Related]
8. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
J Med Assoc Thai; 2002 Nov 28; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[Abstract] [Full Text] [Related]
9. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
Kobayashi T, Kobayashi T, Morikawa A, Ikeda K, Seki M, Shimoyama S, Ishii Y, Suzuki T, Nakajima K, Sakamoto N, Arakawa H.
J Pediatr; 2013 Aug 28; 163(2):521-6. PubMed ID: 23485027
[Abstract] [Full Text] [Related]
10. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
J Med Assoc Thai; 2003 Aug 28; 86 Suppl 3():S656-60. PubMed ID: 14700163
[Abstract] [Full Text] [Related]
11. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
Arch Dis Child; 2008 Feb 28; 93(2):142-6. PubMed ID: 17962370
[Abstract] [Full Text] [Related]
12. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature.
Athappan G, Gale S, Ponniah T.
Cardiovasc J Afr; 2009 Feb 28; 20(4):233-6. PubMed ID: 19701534
[Abstract] [Full Text] [Related]
13. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A, KAICA trial Investigators.
Lancet; 2019 Mar 16; 393(10176):1128-1137. PubMed ID: 30853151
[Abstract] [Full Text] [Related]
14. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A.
J Pediatr; 2006 Sep 16; 149(3):336-341. PubMed ID: 16939743
[Abstract] [Full Text] [Related]
15. Kawasaki disease: part II. Complications and treatment.
Bayers S, Shulman ST, Paller AS.
J Am Acad Dermatol; 2013 Oct 16; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
[Abstract] [Full Text] [Related]
16. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
[Abstract] [Full Text] [Related]
17. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.
Zhu BH, Lv HT, Sun L, Zhang JM, Cao L, Jia HL, Yan WH, Shen YP.
Eur J Pediatr; 2012 Mar 26; 171(3):571-8. PubMed ID: 22057683
[Abstract] [Full Text] [Related]
18. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
Durongpisitkul K, Gururaj VJ, Park JM, Martin CF.
Pediatrics; 1995 Dec 26; 96(6):1057-61. PubMed ID: 7491221
[Abstract] [Full Text] [Related]
19. Advances in the treatment of Kawasaki disease.
Dominguez SR, Anderson MS.
Curr Opin Pediatr; 2013 Feb 26; 25(1):103-9. PubMed ID: 23283289
[Abstract] [Full Text] [Related]
20. [Risk factors for coronary artery lesions in children with Kawasaki disease].
Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec 26; 14(12):938-41. PubMed ID: 23234782
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
